Search

Your search keyword '"Bachelez H"' showing total 852 results
Start Over Author "Bachelez H"
852 results on '"Bachelez H"'

201. Cholangite neutrophilique et psoriasis

Author

Dieudé, P., primary, Sbidian, E., additional, Viguier, M., additional, Zafrani, E., additional, de Bazelaire, C., additional, Dawidowicz, K., additional, Adle-Biassette, H., additional, Allez, M., additional, Petit, A., additional, Richette, P., additional, and Bachelez, H., additional

Published
2012
Full Text
View/download PDF

202. Switchs de biothérapies chez les patients atteints de psoriasis modéré à sévère dans la cohorte française PSOBIOTEQ

Author

Curmin, R., Guillo, S., De Rycke, Y., Bachelez, H., Beylot-Barry, M., Beneton, N., Olivier, C., Dupuy, A., Joly, P., Jullien, D., Richard, M., Viguier, M., Sbidian, E., Paul, C., Mahé, E., and Tubach, F.

Abstract

Les biothérapies constituent la pierre angulaire du traitement des patients atteints de psoriasis en plaques modéré à sévère et les passages d'une molécule à une autre, appelés “switchs”, sont souvent nécessaires pour maintenir l'efficacité clinique au cours du temps. L'objectif principal de cette étude était de décrire précisément ces changements de biothérapies et leur évolution au cours du temps avec l'arrivée sur le marché de nouvelles molécules. L'objectif secondaire était d’évaluer les facteurs associés au type de switch (intra-classe - c'est-à-dire au sein de la même classe thérapeutique - versus inter-classe) chez les patients exposés initialement à un inhibiteur du TNF-alpha.

Published
2022
Full Text
View/download PDF

204. Hematological malignancy associated with polymyositis and dermatomyositis

Author

Marie, I., primary, Guillevin, L., additional, Menard, J.-F., additional, Hatron, P.Y., additional, Cherin, P., additional, Amoura, Z., additional, Cacoub, P., additional, Bachelez, H., additional, Buzyn, A., additional, Le Roux, G., additional, Ziza, J.M., additional, Brice, P., additional, Munck, J.N., additional, Sarrot-Reynauld, F., additional, Piette, J.C., additional, and Larroche, C., additional

Published
2012
Full Text
View/download PDF

205. Existe-t-il un retard à l’utilisation des traitements systémiques dans le psoriasis modéré à sévère ?

Author

Paul, C., primary, Maza, A., additional, Richard, M.-A., additional, Aubin, F., additional, Ortonne, J.P., additional, Prey, S., additional, Bachelez, H., additional, Beylot_Barry, M., additional, Bulai-Livideanu, C., additional, Lahfa, M., additional, Nougué, J., additional, Mengual, X., additional, Le Moigne, M., additional, and Lauwers-Cances, V., additional

Published
2011
Full Text
View/download PDF

206. Risque de freination de l’axe surrénalien et d’atrophie cutanée sous dermocorticoïdes dans le psoriasis de l’adulte : analyse systématique de la littérature

Author

Castela, E., primary, Gallini, A., additional, Archier, E., additional, Devaux, S., additional, Paul, C., additional, Aractingi, S., additional, Aubin, F., additional, Bachelez, H., additional, Cribier, B., additional, Joly, P., additional, Jullien, D., additional, Le Maître, M., additional, Misery, L., additional, Richard, M.-A., additional, and Ortonne, J.P., additional

Published
2011
Full Text
View/download PDF

208. Modalités pratiques optimales de prescription des dermocorticoïdes dans le traitement du psoriasis en plaques de l’adulte : revue systématique de la littérature

Author

Castela, E., primary, Gallini, A., additional, Archier, E., additional, Devaux, S., additional, Paul, C., additional, Aractingi, S., additional, Bachelez, H., additional, Cribier, B., additional, Joly, P., additional, Jullien, D., additional, Le Maître, M., additional, Richard, M.-A., additional, and Ortonne, J.-P., additional

Published
2011
Full Text
View/download PDF

210. Prise en charge des herpès HSV2 pseudotumoraux au cours de l’infection par le virus VIH : 10 observations

Author

Sbidian, E., primary, Batistella, M., additional, Lafaurie, M., additional, Bouscarat, F., additional, Bézier, M., additional, Cavelier-Balloy, B., additional, Vilmer, C., additional, Le Goff, J., additional, Agbalika, F., additional, Molina, J.-M., additional, Bagot, M., additional, Simon, F., additional, Janier, M., additional, and Bachelez, H., additional

Published
2011
Full Text
View/download PDF

212. PSS28 DEVELOPMENT OF AN INSTRUMENT MIRRORING PATIENT AND PHYSICIAN PERCEPTION OF PSORIASIS SEVERITY AND TREATMENT EFFECT

Author

Roborel, de, primary, Climens, A, additional, Marant, C, additional, Arnould, B, additional, Bachelez, H, additional, Bagot, M, additional, Beaulieu, P, additional, Joly, P, additional, Jullien, D, additional, Le Maitre, M, additional, Ortonne, JP, additional, Paul, C, additional, Contreras, L, additional, and Thibout, E, additional

Published
2010
Full Text
View/download PDF

216. Apparition de novo d'un rhumatisme psoriasique chez des patients traités par Efalizumab pour un psoriasis cutané: un effet secondaire inattendu d'une nouvelle biothérapie dans le psoriasis

Author

Richette, P., primary, Viguier, M., additional, Aubin, F., additional, Lahfa, M., additional, Beylot-Barry, M., additional, Bedane, C., additional, Delesalle, F., additional, Richard-Lallemand, M.A., additional, Delaporte, E, additional, Dubertret, L., additional, Bardin, T., additional, and Bachelez, H., additional

Published
2007
Full Text
View/download PDF

220. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.

Author

Reich, K., Zschocke, I., Bachelez, H., Jong, E.M.G.J., Gisondi, P., Puig, L., Warren, R.B., and Mrowietz, U.

Subjects
PSORIASIS, PSORIASIS treatment, CALCITRIOL, DISEASES in adults, DRUG efficacy, RANDOMIZED controlled trials, PATIENTS, THERAPEUTICS
Abstract

Background Psoriasis is a common, chronic, inflammatory skin disease with the majority of individuals having limited disease, treated with topical medication. However, special attributes of topical treatments like galenic/cosmetic properties or an inconvenient treatment schedule may result in low preference for topical treatments. Hence, there is strong medical need for a topical medication, which is highly efficacious, easy-to-use and preferred by both physicians and patients. Objective Blinded interim analysis with the purpose to assess efficacy of (both from the physician's and patient's perspective) and the patients' preference with a highly efficacious and easy-to-use fixed combination of calcipotriol/betamethasone dipropionate topical gel after 8 weeks of once daily treatment in a large patient population. Methods In this phase IV, international, multicentre, randomized, controlled, prospective, parallel group study, adult patients with active, mild to moderate psoriasis despite previous topical psoriasis treatment, i.e. unsuccessful in the 8 weeks preceding study participation, are followed over 64 weeks. During the first 8 weeks the patients apply their medication once a day followed by a 56-weeks maintenance period according to Sm PC. Blinded interim analysis of all patients included demographics, Physician's Global Assessment, the novel Patient's self Global Assessment (Ps GA) and Patient Preference Questionnaire ( PPQ). Results 1795 patients were analysed. At week 8, 36.5% of the physicians rated the patients' psoriasis as clear/almost clear. Similarly, based on the patients' self-assessment, 34.2% had a clear/almost clear score of Ps GA in week 8. Analysis of the PPQ showed that the vast majority of the patients judged their 8-week treatment to be preferable compared with their previous treatments. Conclusion Results of this blinded interim analysis indicate that the fixed combination of calcipotriol/betamethasone dipropionate gel is highly efficacious and preferred by the majority of analysed patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

221. Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity ( REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians.

Author

Gilet, H., Roborel de Climens, A., Arnould, B., Bachelez, H., Bagot, M., Beaulieu, P., Joly, P., Jullien, D., Le Maître, M., Ortonne, J.P., Paul, C., and Thibout, E.

Subjects
PSORIASIS treatment, TREATMENT effectiveness, PSORIASIS, DISEASE risk factors, MEDICAL decision making, PSYCHOMETRICS, MEDICAL statistics
Abstract

Background To date, there is no global consensus on the definition of the severity of psoriasis. The REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire has recently been developed to provide a better understanding of plaque-type psoriasis severity and treatment efficacy from both patient and clinician perspectives. Objective This study aimed to develop and psychometrically validate the new REFLETS questionnaire to evaluate patient and clinician perceptions of plaque-type psoriasis severity and treatment efficacy. Methods Two similar versions of the REFLETS questionnaire were developed following a rigorous methodology for clinicians and patients, referring to 'the psoriasis of your patient' or to 'your psoriasis', respectively. An observational, longitudinal, multicentre study was conducted in France with 34 dermatologists and 430 mild to severe plaque-type psoriasis patients to finalize the questionnaire and evaluate its psychometric properties. Results Two dimensions were defined - severity and treatment efficacy - with three subdimensions within severity (impact of psoriasis, symptoms and disease course), and two individual items on joint pain. The questionnaire was well accepted by clinicians and patients. Excellent internal consistency (Cronbach's alpha = 0.66-0.98) and test-retest reliability (intraclass correlation coefficients = 0.83-0.94) were demonstrated. REFLETS scores were moderately to highly correlated to Psoriasis Area and Severity Index ( r = 0.35-0.70), Skindex-29 ( r = 0.46-0.82) and DLQI scores ( r = 0.36-0.82). Patients with decreased psoriasis severity and those with increased treatment efficacy, according to patient global evaluations, had lower severity and higher treatment efficacy REFLETS scores, respectively. Conclusion REFlective evaLuation of psoriasis Efficacy of Treatment and Severity is a promising tool for assessing plaque-type psoriasis severity and treatment efficacy from patient and clinician perspectives. It may help to improve patient and clinician communication in treatment decision making. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

241. Tanorexie et psoriasis sévère

Author

Mahé, E., Curmin, R., Paul, C., Bachelez, H., Sbidian, E., Beylot-Barry, M., Beneton, N., Dupuy, A., Joly, P., Jullien, D., Richard, M.A., Viguier, M., Chosidow, O., and Tubach, F.

Abstract

La tanorexie est une addiction comportementale qui consiste en « l’envie irrépressible de s’exposer aux ultraviolets ». Elle toucherait 5 à 10 % de la population, plus souvent les femmes.

Published
2022
Full Text
View/download PDF

242. Impact de la voie d’administration du méthotrexate sur son maintien en monothérapie dans le psoriasis cutané : données issues de la cohorte PSOBIOTEQ

Author

Paris, C., Gouillon, L., Curmin, R., De, R.Y., Bachelez, H., Beneton, N., Beylot-Barry, M., Dupuy, A., Joly, P., Mahé, E., Paul, C., Richard, M.A., Sbidian, E., Viguier, M., Chosidow, O., Tubach, F., and Jullien, D.

Abstract

On dispose de peu de données sur l’impact de la voie d’administration du méthotrexate (MTX) sur son maintien en monothérapie dans le psoriasis cutané. L’objectif principal était d’évaluer l’impact du mode d’administration initial du MTX sur son maintien et sur le délai avant initiation d’un autre traitement, chez les patients avec un psoriasis cutané modéré à sévère. Les objectifs secondaires étaient de décrire les causes d’arrêt en fonction de la voie d’administration, et la ligne de traitement prescrite en relais.

Published
2022
Full Text
View/download PDF

245. Quoi de neuf en thérapeutique dermatologique ?

Author

Bachelez, H.

Abstract

L’année en cours a vu la publication de résultats d’essais thérapeutiques qui ouvrent de nouvelles perspectives pour le traitement des dermatoses inflammatoires et dysimmunitaires chroniques. Si la pathologie privilégiée par les thérapeutiques innovantes ciblées reste le psoriasis, les indications tendent à se diversifier vers d’autres dermatoses qui, dans leurs formes modérées à sévères, ont un impact important sur la qualité de vie des malades, comme l’hidradénite suppurée et la dermatite atopique de l’adulte. Ainsi, le développement des inhibiteurs de l’IL-17 et de l’IL-23, mais aussi de petites molécules comme le tofacitinib dans le psoriasis, et l’achèvement des études de phase 2 avec le dupilumab, inhibiteur de l’IL-4 et de l’IL-13, dans la dermatite atopique sévère de l’adulte, ont permis de démontrer l’efficacité importante de ces traitements ; l’adalimumab est le premier traitement à obtenir une autorisation de mise sur le marché (AMM) européenne dans l’hidradénite suppurée. Par ailleurs, les progrès en vaccinologie ont permis l’achèvement d’essais importants à grande échelle, démontrant l’efficacité et la sécurité d’emploi de nouveaux vaccins antizosteriens, et nonavalent antipapillomavirus humain. Pour toutes ces interventions, une pharmacovigilance prolongée en vie réelle sera nécessaire, afin de donner une image plus précise de leur balance bénéfice-risque.

Published
2015
Full Text
View/download PDF

246. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis.

Author

Tauber, M., Viguier, M., Alimova, E., Petit, A., Lioté, F., Smahi, A., and Bachelez, H.

Subjects
INTERLEUKIN-1 receptor antagonist protein, PSORIASIS treatment, DRUG efficacy, SKIN diseases, DERMATOLOGY
Abstract

Background Palmoplantar pustular psoriasis is a clinical psoriasis variant characterised by a high impact on quality of life and poor response to biologics approved for plaque type psoriasis.The recombinant interleukin-1 ( IL-1) receptor antagonist anakinra has been recently used for the treatment of isolated refractory cases of generalised pustular psoriasis with contrasted results. Objectives To report the clinical response in two patients treated with anakinra as salvage therapy in two patients with severe palmoplantar pustular psoriasis refractory to currently available antipsoriatic systemic therapies. Methods Anakinra was given subcutaneously at the daily dose of 100 mg, and clinical response was evaluated using the palmoplantar psoriasis area and severity index ( PPPASI). Results Only partial and transient responses were observed in both patients, who had to stop anakinra due to lack of efficacy and to side effects. Conclusion Anakinra appears to provide only partial clinical improvement in refractory palmoplantar pustular psoriasis. Prospective clinical studies on larger populations are warranted to investigate more accurately both efficacy and safety of IL-1-inhibiting strategies in pustular psoriasis. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

247. Psoriasis associated with idiopathic CD4+ T-cell lymphopenia: a regulatory T-cell defect?

Author

Baroudjian, B., Viguier, M., Battistella, M., Beneton, N., Pagès, C., Gener, G., Bégon, E., and Bachelez, H.

Subjects
PSORIASIS, T cells, IMMUNOLOGICAL deficiency syndromes, IMMUNODEFICIENCY, SKIN diseases
Abstract

Idiopathic CD4+ lymphocytopenia ( ICL) is a rare immunodeficiency syndrome of unknown origin for which the increased risks of opportunistic infections and of malignancies have been well established; however, skin dysimmune diseases, including psoriasis, have been scarcely reported up to now. We report herein the severe course of psoriasis in four patients with ICL, and show evidence for a defect in the skin recruitment of regulatory CD4+ Fox P3+ T cells. These data raise the apparent paradigm of the occurrence of a severe immunomediated disease together with a profound T-cell defect, a model that might also apply to other immune deficiencies associated with psoriasis. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

248. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.

Author

Masson, A., Guitera, P., Brice, P., Moulonguet, I., Mouly, F., Bouaziz, J. ‐ D., Battistella, M., Madelaine, I., Roux, J., Ram ‐ Wolff, C., Cayuela, J. ‐ M., Bachelez, H., BENsussan, A., Michel, L., and Bagot, M.

Subjects
ALEMTUZUMAB, DRUG efficacy, T-cell lymphoma, SKIN disease treatment, ANTINEOPLASTIC agents, THERAPEUTICS
Abstract

Background Alemtuzumab has been proposed as salvage therapy for refractory cutaneous T-cell lymphomas ( CTCLs). Long-term follow-up data are scarce. Objectives To assess the efficacy and safety of alemtuzumab in the treatment of advanced CTCL. Methods A multicentre retrospective analysis was carried out of 39 patients with advanced CTCL treated with alemtuzumab between 2003 and 2013. Results Thirty-nine patients (median age 62 years, range 20-83) with Sézary syndrome ( SS, n = 23) or advanced mycosis fungoides ( MF, n = 16) received alemtuzumab 30 mg two to three times per week for a median duration of 12 weeks (range 1-35). Fifteen patients received maintenance therapy for a median duration of 24 weeks (range 6-277). Eleven patients (28%) had transformed disease ( MF, n = 10; SS, n = 1). After a median follow-up of 24 months (range 0·3-124), eight patients (21%) were still alive. The overall response rate was 51% in the whole study group (partial response, n = 13; complete response, n = 7); 70% in patients with SS and 25% in patients with MF ( P = 0·009). The median time to progression was 3·4 months (range 0·4-42). Six patients (15%; SS, n = 5; MF, n = 1) remained progression free for > 2 years (median 56 months, range 28-117). Five patients experienced cutaneous large T-cell transformation during alemtuzumab treatment and one patient developed primary cutaneous large B-cell lymphoma. Twenty-four patients (62%) had a grade three or higher infectious adverse event and 10 (26%) a haematological toxicity, which led to treatment discontinuation in 17 cases (44%) and death in two (5%). Conclusions Alemtuzumab may induce long-term remission in SS but seems ineffective in MF and transformed CTCL. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results